论文部分内容阅读
目的对三联疗法在临床中治疗消化性溃疡的临床疗效进行分析。方法 60例消化性溃疡患者,随机分为实验组与对照组,每组30例。实验组患者临床给予雷贝拉唑、阿莫西林、克拉霉素三联疗法治疗;对照组患者临床给予奥美拉唑、阿莫西林、克拉霉素三联疗法治疗。对比两组患者的临床疗效、不良反应发生率。结果实验组总有效率96.7%高于对照组80.0%,差异具有统计学意义(χ~2=4.043,P<0.05)。实验组不良反应发生率3.3%低于对照组23.3%,差异具有统计学意义(χ~2=5.192,P<0.05)。结论在临床中应用雷贝拉唑、阿莫西林、克拉霉素三联疗法对消化性溃疡患者进行治疗,能够显著的提高患者的临床疗效水平,改善患者的临床症状,并能够有效的降低药物带来的毒副作用,降低患者的不良反应。
Objective To analyze the clinical efficacy of triple therapy in the treatment of peptic ulcer in clinic. Methods Sixty patients with peptic ulcer were randomly divided into experimental group and control group, 30 cases in each group. Rabeprazole, amoxicillin and clarithromycin triple therapy were given to the experimental group. Omeprazole, amoxicillin and clarithromycin triple therapy were given to the patients in the control group. Comparison of two groups of patients clinical efficacy, adverse reactions. Results The total effective rate in experimental group was 96.7% higher than that in control group (80.0%), the difference was statistically significant (χ ~ 2 = 4.043, P <0.05). The incidence of adverse reactions in the experimental group was 3.3% lower than that in the control group (23.3%), the difference was statistically significant (χ ~ 2 = 5.192, P <0.05). Conclusion In the clinical application of rabeprazole, amoxicillin, clarithromycin triple therapy in patients with peptic ulcer treatment, can significantly improve the clinical efficacy of patients, to improve the clinical symptoms, and can effectively reduce the drug band To the side effects, reduce adverse reactions in patients.